Key result
ROMA-CV framework enhances SCORE2 cardiovascular risk assessment with routine Lp(a) and selective imaging.
Why the study?
CVD remains the leading cause of EU mortality with Romania ranking second highest, yet current primary-prevention risk frameworks like SCORE2/SCORE2-OP and PCE diverge on patient selection and have limitations in this very-high-risk setting.
The proposed ROMA-CV algorithm adapts existing ESC and ACC/AHA guidelines to address the limitations of SCORE2 in Romania, a very-high-risk country, by integrating Lp(a) testing, risk amplifiers, and imaging.
Answers are grounded in this paper and cite their sources.
May support tailored Romanian risk assessment; leaves open prospective validation of ROMA-CV before clinical adoption.
Background: Cardiovascular disease (CVD) remains the leading cause of mortality across the European Union (EU), with a fourfold to fivefold east–west gradient in standardized circulatory-disease mortality. Romania ranks second highest in the EU (787 per 100,000 inhabitants in 2023). Primary-prevention practice is organized around two quantitative frameworks—the 2021 European Society of Cardiology (ESC) SCORE2/SCORE2-OP system and the 2018/2019 American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations (PCE)—which converge on therapy but diverge on patient selection. Methods: We conducted a structured narrative review (SANRA-compliant) of contemporary primary-prevention guidelines, validation studies, key trials of risk-modifier interventions, and Romanian epidemiological data through April 2026. On this basis, we developed ROMA-CV (Risk Of Multifactorial Atherosclerosis—CardioVascular) as a conceptual, country-specific risk-stratification framework anchored to existing Class I/IIa recommendations or Level A/B evidence, rather than as a fully developed, ready-to-use clinical tool Results: Four structural limitations of SCORE2 are clinically consequential in Romania: (i) an age floor of 40 years that excludes the population in which premature myocardial infarction is most preventable; (ii) a country-level calibration coefficient applied to individuals; (iii) permissive treatment of lipoprotein(a) [Lp(a)]; and (iv) an under-emphasis of subclinical-atherosclerosis imaging. We propose ROMA-CV (Risk Of Multifactorial Atherosclerosis—Cardiovascular), a four-step algorithm retaining SCORE2 as the quantitative spine while embedding once-in-a-lifetime Lp(a) measurement, a mandatory amplifier checklist, and selective coronary artery calcium (CAC) or carotid/femoral ultrasound imaging. Conclusions: ROMA-CV is a hypothesis-generating proposal that operationalizes existing evidence-based recommendations into a deterministic Romanian pathway aligned with the 2025–2030 Romanian National Plan for Non-Communicable Diseases and the EU Cardiovascular Health Plan. The algorithm is not a validated clinical decision tool and requires prospective external validation in Romanian cohorts—alongside feasibility, cost-effectiveness, and implementation studies—before any consideration of routine clinical adoption.
No takes yet. Share an insight, caveat, or question.
Brie et al. (2026) conducted a review in Cardiovascular disease. ROMA-CV Algorithm vs. SCORE2 was evaluated. The authors propose ROMA-CV, a four-step cardiovascular risk assessment algorithm for Romania that retains SCORE2 while embedding once-in-a-lifetime Lp(a) measurement, a mandatory amplifier checklist, and selective imaging.
Synapse has enriched 10 related papers. Consider them for comparative context: